ValiRx says patient recruitment for lung cancer study has been completed
VAL-401 is being developed jointly by ValiRx and Tangent Reprofiling as part of the pair’s ValiSeek collaboration.
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 10 of 16
FTSE 100 closes 55 down and UK mid-caps plunge; BoE raises prospect of rate rise
FTSE 100 closed down 55 at 7,419 as retail shares took a beating
ValIRx joint venture picks up patent in Australia for lung cancer compond
The drug is currently progressing through a Phase ll trial in Georgia with dosing to be completed by the end of 2017.
Investments and investor services
FTSE 100 closes higher as traders await Fed minutes
The FTSE 100 index closed up 29.61 at 7,514 with easyJet the biggest gainer
Archive
Proactive news round-up: Kibo Mining; DP Poland, Strategic Minerals...
A reverse takeover of Opera Investments is the method for the deal with the name of the company to be changed to Katoro Gold PLC to reflect the new business focus.
ValiRx happy with prostate and lung cancer drug trial progress
The AIM-listed group has two drugs currently in clinical trial: VAL201 for prostate cancer; and VAL401 for lung cancer.
Telit Communications shares slip after announcing £39mln cash call
Telit Communications shares have fallen after announcing a fundraising while Diversified Gas & Oil has gained on acquisition news
FTSE 100 rises as US non-farm payrolls report beats expectations
London's top tier index rose 22 points to 7,270.88 at 2.38pm after a better-than-expected US non-farm payrolls report
ValiRx offers low-risk, high return for investors, says analyst
ValiRx shares have gained today after Beaufort issued a 'speculative buy' rating and a target price of 6.0p
Restaurant Group back on menu on signs of stability
Some of the top rises and falls in London at 3.30pm: Restaurant Group, Inmarsat, Graphene Nanochem
ValiRx to publish mid-trial data from lung cancer study
A second clinic in Tbilisi, Georgia, has just started recruiting patients
Investments and investor services
FTSE 100 ended lower despite sterling weakness and Budget boost to builders
FTSE 100 shares ended down on Wednesday with sterling nursing a seven-week low despite a lift for construction stocks following the UK Finance Minister’s Budget pledge of a mini Trump boost to infrastructure
ValiRx raises £1.2mln to support clinical trial programmes
Certain directors of the company will be subscribing for £30,000 of shares at the same price as the share placing
ValiRx and Faron highlight different sides of pharma funding
Some the largest rises and fall at 3pm: ValiRx, Faron, Jersey Oil
ValiRx's cancer treatment recognised in peer-reviewed journals
ValiRx has been published in two journal articles for its work on developing drugs for cancer treatment
Archive
Webis sales rise not enough to offset margin concerns
Some the largest share price rises and fall in London at 3pm: Webis, Wey Education, ValiRx